Press Release History | Oxurion — Advancing Science. Enhancing Vision

Delivering next-generation treatments for back of the eye disorders, with focus on diabetic eye disease

THR-149 - Press Releases archive

25 May 2018

ThromboGenics Enrolls First Patient in Phase 1 Clinical Study Evaluating THR-149, a plasma kallikrein inhibitor, for treatment of Diabetic Macular Edema (DME)

23 May 2018

ThromboGenics to present a preclinical overview of its two most advanced diabetic eye disease clinical candidates, THR-317 and THR-149, at EASDec 2018

6 Apr 2018

ThromboGenics announces publication in The Journal of Medicinal Chemistry of preclinical data supporting therapeutic potential of THR-149

20 Apr 2017

ThromboGenics Achieves Important Milestone in the Development of THR-149, A Novel Plasma Kallikrein Inhibitor for Diabetic Macular Edema